These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22850410)

  • 1. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors.
    Gui T; Cao D; Shen K; Yang J; Zhang Y; Yu Q; Wan X; Xiang Y; Xiao Y; Guo L
    Gynecol Oncol; 2012 Nov; 127(2):384-9. PubMed ID: 22850410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
    Gouy S; Arfi A; Maulard A; Pautier P; Bentivegna E; Leary A; Chargari C; Genestie C; Morice P
    Oncologist; 2019 May; 24(5):702-709. PubMed ID: 30201740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients.
    Akman L; Ertas IE; Gokcu M; Terek MC; Sanci M; Sanli UA; Zekioglu O; Ozsaran AA
    J Cancer Res Ther; 2016; 12(1):290-4. PubMed ID: 27072253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian Sertoli-Leydig cell tumors: an analysis of 13 cases.
    Guo Y; Wang J; Li Y; Wang Y
    Arch Gynecol Obstet; 2020 Jul; 302(1):203-208. PubMed ID: 32430758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.
    Sigismondi C; Gadducci A; Lorusso D; Candiani M; Breda E; Raspagliesi F; Cormio G; Marinaccio M; Mangili G
    Gynecol Oncol; 2012 Jun; 125(3):673-6. PubMed ID: 22446621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian Sertoli-Leydig cell tumor: a report of seven cases and a review of the literature.
    Xiao H; Li B; Zuo J; Feng X; Li X; Zhang R; Wu L
    Gynecol Endocrinol; 2013 Mar; 29(3):192-5. PubMed ID: 23173550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
    Cicin I; Saip P; Guney N; Eralp Y; Ayan I; Kebudi R; Topuz E
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sertoli-Leydig cell tumor of the ovary: Analysis of a single institution database and review of the literature.
    Durmuş Y; Kılıç Ç; Çakır C; Yüksel D; Boran N; Karalök A; Boyraz G; Turan AT
    J Obstet Gynaecol Res; 2019 Jul; 45(7):1311-1318. PubMed ID: 31106943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database.
    Bhat RA; Lim YK; Chia YN; Yam KL
    J Obstet Gynaecol Res; 2013 Jan; 39(1):305-10. PubMed ID: 22691037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes analysis of ovarian Sertoli-Leydig cell tumors (SLCTs): analysis of 15 patients.
    Wang G; Zhang R; Li C; Chen A
    J Ovarian Res; 2021 Nov; 14(1):150. PubMed ID: 34736487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of advanced ovarian juvenile granulosa cell tumors.
    Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
    Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
    Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
    Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertoli-Leydig cell tumors of the ovary: a Taiwanese Gynecologic Oncology Group study.
    Weng CS; Chen MY; Wang TY; Tsai HW; Hung YC; Yu KJ; Chiang YC; Lin H; Lu CH; Chou HH
    Taiwan J Obstet Gynecol; 2013 Mar; 52(1):66-70. PubMed ID: 23548221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
    Gressel GM; Buza N; Pal L
    Eur J Gynaecol Oncol; 2017; 38(2):214-220. PubMed ID: 29953783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor].
    Li B; Wu LY; Zhang WH; Li L; Ma SK; Liu LY
    Zhonghua Fu Chan Ke Za Zhi; 2004 May; 39(5):334-7. PubMed ID: 15196418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
    Low JJ; Perrin LC; Crandon AJ; Hacker NF
    Cancer; 2000 Jul; 89(2):391-8. PubMed ID: 10918171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features of ovarian Sertoli-Leydig cell tumors.
    Zhang HY; Zhu JE; Huang W; Zhu J
    Int J Clin Exp Pathol; 2014; 7(10):6956-64. PubMed ID: 25400781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.